Athena diagnostics improves ataxia movement disorder testing with novel long-read gene sequencing

New test utilizes technology based on pacbio's puretarget sequencing method to uncover genetic causes of disease boston , july 29, 2025 /prnewswire/ -- athena diagnostics, the specialty neurology business of quest diagnostics (nyse: dgx), a leading provider of diagnostic information services, today announced a new laboratory test service intended to provide insights into genetic causes of ataxia, a group of progressive, degenerative neurological disorders that affect movement or coordination. the new service is a laboratory developed test that identifies sequences of dna that repeat many times across a long stretch of the genome.
DGX Ratings Summary
DGX Quant Ranking